Activating mutations in the platelet-derived growth factor (PDGF) receptor alpha (PDGFRA) have been described in patients with gastrointestinal stromal tumors or myeloid malignancies associated with hypereosinophilia. These patients respond well to imatinib mesylate, raising the question as to whether patients with a PDGF receptor mutation in other tumor types should receive a tyrosine kinase inhibitor treatment. We characterized 10 novel somatic point mutations in PDGFRA that have been reported in isolated cases of glioblastoma, melanoma, acute myeloid leukemia, peripheral nerve sheath tumors and neuroendocrine carcinoma. The PDGFRA transmembrane domain mutation V536E stimulated Ba/F3 cell growth and signaling via ERK and STAT5 in the absence of ligand. This mutant, identified in glioblastoma, was strongly inhibited by imatinib. Modeling suggested that the mutation modulates the packing of the transmembrane domain helices in the receptor dimer. By contrast, two mutations in highly conserved residues affected the receptor traffic to the cell surface or kinase activity, thereby preventing the response to PDGF. The other mutations had no significant impact on the receptor activity. This functional analysis matched the predictions of SIFT and PolyPhen for only five mutations and these algorithms do not discriminate gain from loss of function. Finally, an E996K variant that had been identified in a melanoma cell line was not expressed in these cells. Altogether, several newly identified PDGFRA mutations do not activate the receptor and may therefore represent passenger mutations. Our results also underline the importance of characterizing novel kinase alterations in cancer patients.
INTRODUCTION
Platelet-derived growth factor (PDGF) receptors are receptor tyrosine kinases that are required for the embryo development. 1 Two genes, PDGFRA and PDGFRB, encode the receptor a and b isoforms, which are highly homologous and share a common architecture. They consist of five N-terminal immunoglobulin (Ig)-like domains, which are binding to various isoforms of PDGF, a single transmembrane domain and a split protein tyrosine kinase domain. Although the exact structure of these receptors has not been solved yet, the mechanism of activation could be modeled based on mutation analysis and the partial structure of related receptors such FLT3 and KIT. In the absence of ligand, the juxtamembrane domain and the activation loop adopt a conformation that keeps the kinase domain inactive. PDGF binding induces the receptor dimerization and both inhibitory domains undergo large conformation changes and become phosphorylated on tyrosines, stabilizing the active receptor state. In PDGF receptor b (PDGFRB), the C-terminal tail was also suggested to have an inhibitory role. 2 This was not investigated in PDGFRA; its C-terminus being the most divergent part compared with PDGFRB.
Activating point mutations in PDGFRA have been described in a small subset of patients with gastrointestinal stromal tumors (GIST, 5-10%). 3, 4 Most mutations are located in the juxtamembrane domain or in the activation loop and are likely to disrupt the inhibited conformation of the kinase domain while stabilizing the active one. Activated fusions genes, such as FIP1L1-PDGFRA, were described in myeloid malignancies associated with hypereosinophilia (MMAH). [5] [6] [7] In most cases, the fusion disrupts the juxtamembrane domain, which is enough to activate the receptor. Alternatively, the fusion partner includes an oligomerization domain, which activates the kinase activity, such as in most PDGFRB fusions. Recently, somatic PDGFRA point mutations were also found in hypereosinophilia. 8 Interestingly, some of the reported mutations were not transforming when tested in cell lines. Gain-of-function PDGFRA mutations were also reported in inflammatory fibroid polyps. 9 In addition, PDGFRA is activated by overexpression in glioblastoma of the proneural subtype. 10 An in-frame deletion of 81 amino acids in the Ig-like domains 4 and 5 was found to activate PDGFRA in glioblastoma patients with a receptor gene amplification. 11, 12 The PDGF receptor kinase activity is effectively inhibited by imatinib mesylate (Glivec), a tyrosine kinase inhibitor developed against BCR-ABL, which turned out to be at least 10 times more active on PDGF receptors.
in myeloid malignancies associated with hypereosinophilia in the presence of a PDGF receptor fusion gene. 13, 14 GISTs are also sensitive to imatinib, although resistant mutations such as D842V have been described. 4 New molecules may overcome resistance. By contrast, imatinib has failed to improve survival of glioblastoma patients. 15, 16 The success of imatinib in cancers carrying an activating PDGFRA variant, that is, GIST and MMAH, raises the question as to whether all cancer patients with a PDGF receptor mutation should receive a tyrosine kinase inhibitor treatment. Even though these patients are rare, next-generation sequencing technologies will allow the systematic detection of many different mutations in most cancers. These new technologies have raised great expectations for the development of a personalized treatment of each cancer.
Ten novel somatic point mutations in PDGFRA have been reported in a variety of cancers, namely isolated cases of glioblastoma, melanoma, acute myeloid leukemia (AML), peripheral nerve sheath tumors and neuroendocrine carcinoma (Table 1) . 10, [17] [18] [19] [20] The mutations were found in single cases, except W349C and V536E, which were reported in two patients. 10, 21 In most cases, a polymorphism was carefully excluded. However, they were not functionally characterized and it is not clear whether these patients could have benefited from imatinib therapy. The mutations are located in various domains of the receptor, including regions where activating mutations have not been reported yet, such as the transmembrane domain and the C-terminal tail. The goal of the present study was to characterize them.
RESULTS
W349C prevents PDGFRA glycosylation and traffic to the cell surface Mutants were stably transfected in Ba/F3 cells, which proliferate in the absence of cytokine when they express a constitutively activated PDGF receptor. 4, 22 As a positive control, we also expressed PDGFRA-D842V, a constitutively activated mutant found in GISTs. 4 The mutant Ba/F3 lines were sorted to remove the fraction of cells that did not express PDGFRA. Their cell surface expression after sorting is shown in Figure 1a . W349C was not detectable at the cell surface and could not be sorted. Next, the receptor expression level was analyzed by western blot (Figure 1b ). All mutants were expressed at a level similar or higher than D842V. Two receptor bands are detected by western blots in transfected Ba/F3 cell extracts and represent different N-glycosylation levels, as described. 23 The heavier form corresponds to the fully glycosylated receptor, which is matured in the Golgi and expressed at the cell surface. Unlike wild-type (WT) PDGFRA and the other mutants, W349C was detectable as a single band corresponding to immature glycosylation, indicating that this mutant is not properly trafficking to the cell surface, in agreement with the flow cytometry data (Figure 1b ).
V536E constitutively activates the PDGF receptor
We next tested the proliferation of transfected Ba/F3 cells using a sensitive tritiated thymidine incorporation test. The V536E mutation in the transmembrane domain was the only one supporting Ba/F3 proliferation in the absence of cytokine, like the D842V positive control (Figure 2a ). In the presence of PDGF, the expression of WT or mutant receptors allowed Ba/F3 cell growth to a similar extent, except W349C, as expected from the lack of surface protein expression, and F808L, which did not respond to stimulation. Similar results were obtained by counting cells in liquid cultures in the absence or presence of PDGF (data not shown). All cell lines grew similarly in the presence of interleukin-3 (IL3).
Constitutive signaling by PDGFRA-V536E was confirmed using a luciferase reporter assay driven by serum response elements in MCF7 cells (Figure 2b ). In line with the proliferation results, most mutants were comparable to the WT receptor and only weakly stimulated the reporter activity, except W349C and F808L, which did not produce a significant reporter signal. Similar results were obtained using a promoter driven by signal transducer and activator of transcription (STAT) in PAE cells (Supplementary Figure 1) . The ability of the mutant receptors to respond to PDGF was also tested by co-transfecting a PDGF-B cDNA, which confirmed the inability of the two mutants mentioned above to respond to PDGF.
To further demonstrate that V536E is a transforming mutation, we tested its ability to mediate the formation of transformed fibroblasts foci. Low-passage NIH3T3 cells were transfected with the V536E mutant compared with activated D842V, WT and W349C receptors. In line with the Ba/F3 experiment, PDGFRA-V536E induced the formation of foci, by contrast to WT and W349C receptors (Figure 3a) .
We further studied the V536E mutant signaling in Ba/F3 cells by analyzing STAT5, extracellular signal regulated kinase (ERK)-1/2 and AKT phosphorylation by western blot. The expression of V536E or D842V induced the phosphorylation of ERK and STAT5 but not AKT (Figure 3b) . By contrast, cell stimulation with PDGF induced the phosphorylation of ERK and AKT but not STAT5, suggesting that signal transduction by V536E differed from the WT receptor. The phosphorylation of the receptor itself was then analyzed in transfected HEK293T cells (Figure 3c ). V536E phosphorylation on tyrosines was increased compared with the WT receptor, confirming that this mutation constitutively activates the receptor.
PDGFRA-D842V is resistant to imatinib, whereas juxtamembrane mutants are highly sensitive to this drug. We have also shown previously that a transmembrane deletion shifts the sensitivity of the ETV6-PDGFRB fusion to imatinib. 22 The ability of imatinib to Abbreviations: Ig, immunoglobulin; *, stop codon.
Characterization of novel PDGFRA mutations AI Velghe et al block proliferation and signaling induced by V536E was analyzed in Ba/F3 and MCF7 cells. Figure 4 shows that imatinib completely inhibited Ba/F3-V536E cell growth with an IC50 similar to the one reported for FIP1L1-PDGFRA and much lower than the concentration required to block BCR-ABL. 7 The activation of serumresponsive elements by V536E in luciferase assays was also dampened by imatinib. These experiments demonstrate that V536E is highly sensitive to imatinib.
Impact of V536E on PDGFRA dimerization and structure of the transmembrane domain Mutations similar to V536E in the transmembrane helix of other receptors were suggested to promote dimerization. 24 Therefore, we tested the impact of the V536E mutation on PDGFRA dimerization. Receptor dimers were chemically crosslinked before cell lysis and western blot analysis (Figure 5a ). This experiment suggested that a small fraction of the receptor could be crosslinked in the absence of ligand. Treatment with PDGF then increased the dimer formation, as expected from published results. 25 Importantly, no major difference was observed between WT and mutant receptors.
To understand better the structural origin of the receptor constitutive activation induced by the V536E mutation, we performed molecular modeling of possible conformations of PDGFRA transmembrane helix dimer using PREDDIMER approach. 26 Transmembrane helices of PDGFRA were predicted to form several distinctive top-scoring dimer conformations similar to those of PDGFRB (Figure 5b and Supplementary Figure 2) . We found that the substitution of respective valine for glutamic acid is likely to change the packing efficiency of the predicted dimer conformations and may induce a repopulation of the dimer conformational ensemble. Taking into account an observed gap between packing efficiencies of the transmembrane dimer conformations (calculated according to the scoring function) in mutant V536E receptor, the left-handed conformation is likely to be predominant, whereas the right-handed one is predicted to be less populated (Figure 5c ). In contrast, we observed the reverse situation for WT receptor. In addition, the packing efficiency of both WT conformations are relatively more similar to each other. Finally, the mutation has no effect on the packing efficiency of the parallel transmembrane dimer conformation (Figure 5c ). Previously, nuclear magnetic resonance-derived left-handed conformation of PDGFRB transmembrane dimer (Figure 5b ) was proposed to correspond to activated state of the receptor. 27 Taking together this assumption with results of our modeling, we speculate that the V536E mutation might favor PDGFRA transmembrane dimer in the activated state and obstruct the conformational transition of the receptor to the inactive one. Similar situation has been recently observed by modeling for ErbB2-Neu* V664Q transmembrane mutant, 26 where the analogues mutation increased the dimer packing efficiency The F808L mutant is devoid of kinase activity Proliferation and luciferase assays suggested that the F808L mutant was unable to respond to PDGF stimulation, even though it was expressed at the cell surface. To test the kinase activity of this mutant, we first overexpressed it in HEK293T cells. Figure 6 shows that F808L was not significantly phosphorylated on tyrosines by contrast to WT and D842V receptors. Then, we performed an in vitro kinase assay after receptor immunoprecipitation. The phosphorylation of the WT and D842V receptors was enhanced in the presence of ATP, but F808L remains unphosphorylated, indicating it is a kinase-dead mutant ( Figure 6 ).
The E996K mutant is not expressed in the cell line in which it was identified The E996K mutant was identified in the LB373-MEL cell line, derived from a melanoma metastasis. 19 The mutation was absent in immortalized lymphocytes from the same patient confirming that it was an acquired cancer variant. We confirmed the presence of a heterozygous somatic mutation in the genomic DNA of LB373-MEL (data not shown), but we were unable to detect the PDGFRA protein or transcript, compared with positive controls (Figure 7 ). In conclusion, the E996K mutation, which did not confer any growth advantage in our assays, was not expressed in LB373-MEL cells.
DISCUSSION
Among 10 uncharacterized mutations, V536E was the only gain-of-function variant that we identified. To our knowledge, this is the first cancer mutation described in the PDGF receptors transmembrane domain. A similar V664E mutation in ErbB2/Neu was shown to induce the receptor constitutive tyrosine kinase activity. 24 Activating point mutations in the transmembrane segment have also been found in other receptor tyrosine kinases, such as c-KIT and FGFR3. 3 The insertion of two correctly positioned glutamic residues in a simplified valine-based transmembrane domain is enough to activate PDGFRB and ErbB2/Neu. 28 In addition, the importance of the transmembrane domain for PDGFRB activation was underlined by studies showing that this domain is essential for transformation by the ETV6-PDGFRB fusion and by the bovine papillomavirus E5 protein. 22 It was recently shown that the PDGFRB transmembrane domain is able to form a stable left-handed helical dimer in artificial membranes. 27 In this structure, V543, which is homologous to PDGFRA V536, is located at the edge of the interface (Figure 5a ). The PDGFRA-V539E mutant is likely to populate this dimeric conformation by increasing the packing efficiency of the transmembrane helix dimer, as suggested by modeling. A similar situation was predicted for the rat ErbB2-Neu* V664Q transmembrane mutant. 26 Recently, active and inactive dimer conformations of the EGF receptor transmembrane domain have been reported, supporting the hypothesis that the conformation of this domain has a critical role in receptor tyrosine kinase activation. 29, 30 Our model also predicts that the orientation and the angle between the two helices in the left-handed dimer is affected by the V536E mutation, which may optimally positions the two kinase domains facing each other in the receptor dimer. In conclusion, we suggest that the V536E substitution affects the conformation of the transmembrane domain dimer rather than dimerization itself.
Further experiments are required to decipher the exact mechanism of constitutive PDGF receptor activation by this mutation.
Based on initial reports, PDGFRA mutation screenings in GIST usually focus on exons 12 and 18, which encode the juxtamembrane domain and the activation loop. 4 We suggest that sequencing exon 11, encoding the transmembrane domain, may reveal additional clinically relevant PDGFRA mutations in GIST.
Two mutants, F808L and W349C, did not show any sign of activation and did not respond to PDGF stimulation for different reasons. Interestingly, these two residues were perfectly conserved in vertebrate PDGFRA as well as in the related human receptors PDGFRB, c-KIT, FLT3, CSF1R and VEGFRs (Supplementary Table I ). In the c-KIT structure, W349 mediates key interactions with distant amino acids. 31 This mutation may therefore interfere with PDGFRA folding. The W349C protein appeared as a single immature band and failed to traffic to the plasma membrane. Although a cysteine at position 349 may induce the formation of a new aberrant cysteine bridge, we failed to detect covalent W349C dimeric complex. W349 is also located close to two predicted N-glycosylation sites (N353LT and N359LT). The mutation may thus block the glycosylation of these sites or prevent the traffic to the Golgi where the receptor undergoes its final glycosylation steps. In agreement with its absence at the cell surface, W349C did not respond to the addition of exogenous PDGF. In addition, co-transfection of a PDGF-B cDNA did not activate the mutant receptor either. This may result from the disruption of the Ig-like domain 4, which is essential for PDGFRA signal transduction. 32 The second defective mutation, F808L, is located nearby the activation loop and disrupted the kinase activity. A similar kinase dead mutation has been described in the receptor tyrosine kinase ALK in neuroblastoma. 33 Even if F808L was supporting leukemia development by an unknown mechanism independent of the receptor kinase activity, leukemia patients carrying this mutation are unlikely to benefit from imatinib therapy. Altogether, these two variants likely represent passenger mutations. Nevertheless, we cannot rule out the possibility that they provide an advantage to tumor cells in a particular molecular environment.
Seven mutations produced no particular phenotype and may also be classified as passenger mutations. These residues are conserved in mammalian PDGFRA except V469, which is replaced by an isoleucine in some species (Supplementary Table I ). Interestingly, this valine is substituted by an alanine in Tetraodon nigroviridis, mimicking the V469A mutation found in a malignant peripheral nerve sheath tumor. These seven amino acids are poorly conserved in receptors related to PDGFRA. Remarkably, N870 is replaced by a serine in PDGFRB, supporting our conclusion that N870S does not affect PDGF receptors significantly. The original report did not formally exclude that this allele corresponds to a rare polymorphism rather than a somatic mutation. 18 In the case of E996K, we had access to the original cell line in which this somatic mutation had been identified, 19 but which did not express any detectable PDGFRA protein or transcript. This observation supports the hypothesis that E996K is a passenger mutation, although we cannot rule out the possibility that the receptor was expressed in the original tumor cells and was lost during the adaptation to cell culture.
Three mutations are located in the C-terminal tail, which is unique to PDGFRA, except the last five amino acids, which are also present in PDGFRB. 34 This C-terminal motif, which is lost in the S1049CH* frame shift mutant, 20 was suggested to recruit PTEN via NHERF adaptor proteins, thereby limiting the activation of the PI3K pathway. 35 However, we did not observe any significant increase in PKB phosphorylation downstream this mutant (data not shown). The role of the C-terminal domain of PDGFRA remains to be established.
The occurrence of passenger mutations in cancer genome was highlighted by high throughput sequencing projects. 19, 36 Mutation recurrence in multiple patients has been widely used as a criterion to select driver cancer mutations. In this respect, after the initial submission of the present manuscript, the V536E mutation was described in a second glioblastoma patient. 21 However, W349C was also reported in two patients. 10 The recurrence criterion is also too restrictive because unique cancer variants may be clinically relevant. For instance, several patients with non-recurrent PDGFR fusions genes were successfully treated with imatinib. 3 To predict the impact of single-nucleotide variant on protein function, several algorithms based on sequence homologies and structural data have been developed, such as SIFT and PolyPhen. 37 For five out of eight mutations present in the database, PolyPhen matched our results (Supplementary Table I ). In this set of mutations, the conservation with receptors related to PDGFRA (FLT3, KIT, CSF1R and VEGFRs) was best correlated with the observed functional impact. These tests do not predict whether a given variant leads to a gain of function or a loss of function, a piece of information that is essential in oncology. Therefore, a thorough experimental analysis of cancer mutations remains essential.
After the initial submission of this paper, three novel PDGFRA mutations-among many others-were reported in diffuse large B-cell lymphoma. 38 Based on the criteria mentioned above, they may also represent passenger mutations (Supplementary Table I) .
Our results confirm the occurrence of activating mutations in glioblastoma, in which two activated PDGFRA variants have been previously described. 11, 12 Whether these patients could be more sensitive to kinase inhibitors remains to be studied. By contrast, our observations do not support the existence of driver PDGFRA point mutations in acute myeloid leukemia or malignant peripheral nerve sheath tumors. In the latter tumors, other alterations, namely PDGFRA gene amplification or autocrine loops, may activate WT and mutant receptors. 17 Such alterations have also been described in glioblastomas. 10 The presence of both activating and passenger alterations in glioblastoma, which was also recently reported in idiopathic hypereosinophilia, may reflect a particularly high PDGFRA mutation rate in these cancers. In line with this hypothesis, the proneural subtype of glioblastoma, in which PDGFRA is expressed, is associated with a higher frequency of the hypermutator phenotype. 10 Altogether, we identified a number of key residues for PDGFRA function and characterized a novel type of imatinib-sensitive PDGFRA-activating mutation in the transmembrane segment. Our work underlines the importance of characterizing PDGF receptor mutations in a systematic manner. This is a major issue in the development of personalized targeted therapies.
MATERIALS AND METHODS

Reagents and plasmids
The human PDGFRA cDNA was subcloned in pEF-MYC-CYTO (Invitrogen/ Life Technologies, Gent, Belgium), which allowed a high expression level in Ba/F3, compensating the fast turn-over of the receptor in these cells. 39 A Flag tag was inserted after the signal peptide. Mutations were introduced by Quickchange (Stratagene/Agilent technologies, Diegem, Belgium) and confirmed by sequencing (Macrogen, Seoul, Korea). Western blots were performed as described 34 with anti-PDGFRA (1:200, Santa Cruz, Santa Cruz, CA, USA, #951), PY99 (1:200, Santa Cruz), anti-phospho-Y694-STAT5 (1:1000, Signalway Antibodies, College Park, MD, USA), anti-STAT5, antiphospho-AKT, anti-AKT, anti-phospho-ERK-1/2 (1:1000, Cell Signaling Technologies, Danvers, MA, USA) and anti-ERK2 (1:1000, EET rabbit antiserum 34 ). Imatinib mesylate was purchased from LC Laboratories (Woburn, MA, USA).
Cell culture and transfections HEK293T cells were cultured in Dulbecco's modified Eagle's medium with fetal calf serum (10%) and antibiotics (Invitrogen). Cells were transfected using the calcium phosphate method as described. 39 Ba/F3 cells were cultured in the same medium supplemented with IL3 (200 U/ml). Cells were electroporated as described elsewhere 40 and selected in the presence of G418 (3 mg/ml). Transfected cell populations were sorted by flow cytometry after staining with a monoclonal anti-PDGFRA antibody (R&D systems, Minneapolis, MN, USA, MAB1264) and anti-mouse immunoglobulin labeled with phycoerythrin (Jackson Laboratories, Bar Harbor, ME, USA). A few days later, homogeneous PDGFRA expression was confirmed using the same antibodies by flow cytometry. For proliferation assays, cells were washed three times to remove IL3 and seeded in 96-well plates (10 4 cells/well in 200 ml of medium with 10% serum) without cytokine, with PDGF-BB (20 ng/ml, Peprotec, London, UK) or IL3 (200 U/ml). After 20 h, [ 3 H]-thymidine (0.5 mCi, GE Healthcare, Diegem, Belgium) was added to each well for 4 h. Cells were harvested and the radioactivity incorporated into DNA was counted using a TopCount instrument (Perkin Elmer, Waltham, MA, USA).
LB373-MEL cells were kindly provided by Francis Brasseur (Ludwig Institute for Cancer Research, Brussels, Belgium) and were cultured in Iscove-Dulbecco medium with fetal calf serum (10%) and essential amino acids. Cells were analyzed by flow cytometry as described above. mRNA was extracted using a Qiagen kit and PDGFRA expression was measured by quantitative reverse transcription-PCR as described 41 using AG01518 human fibroblasts and HEPG2 hepatocarcinoma cells as positive and negative controls, respectively. 42 The expression of the house keeping gene RPLP0 was used as control. The sequence of the 996 codon was confirmed by sequencing of multiple clones obtained after PCR amplification of genomic DNA using the oligonucleotides 5 0 -CGTGT GGACTCAGACAATGCA-3 
Transformation assay
Low-passage NIH3T3 cells (American Type Culture Collection, Manassas, VA, USA) were transfected as described. 33, 43 Briefly, 4.5 Â 10 4 cells were seeded the day before into collagen-coated 12-well plates and transfected for 6 h with 0.5 mg of DNA (pEF-MYC-CYTO vector containing PDGFRA WT, D842V, V536E or W349C) and 1.4 ml of Lipofectamine 2000 in 0.3 ml of Opti-MEM (both from Invitrogen). Twenty-four hours after transfection, threefifth of the cells from each well were transferred to wells in collagen-coated six-well plates and kept in Dulbecco's modified Eagle's medium (10% fetal calf serum and 0.5 mg/ml G418) until the cells reached confluence. Thereafter, cells were kept in Dulbecco's modified Eagle's medium (5% fetal calf serum and 0.25 mg/ml G418) for approximately 10 days. Three weeks after transfection, the cells were fixed using methanol and plates were stained with crystal violet.
Western blot, immunoprecipitation and crosslinking
These experiments were performed essentially as described. 22, 44 Briefly, Ba/F3 cells expressing PDGFRA were washed and incubated in the absence of IL3 for 4 h. In signaling studies, cells were restimulated for 15 min with PDGF-BB (25 ng/ml) or IL3 (200 U/ml) at 37 1C, washed and lysed in SDS-polyacrylamide gel electrophoresis sample buffer. For crosslinking studies, 2 Â 10 6 cells were stimulated with PDGF-BB (100 ng/ml) for 1 h on ice to prevent endocytosis. Cells were washed with phosphate-buffered saline and treated with bis(sulfosuccinimidyl)-suberate (Pierce/Thermoscientific, Rockford, IL, USA, 1 mM) for 1 h on ice in 200 ml phosphatebuffered saline. Glycine (3.5 mM, final concentration) was then added to stop the reaction before protein extraction in lysis buffer. PDGF receptors were isolated with wheat germ agglutinin-coupled agarose beads (SigmaAldrich, St Louis, MO, USA). Beads were extensively washed and proteins were eluted with sample buffer for western blot analysis with anti-PDGFRA antibodies.
Luciferase assays MCF7 and PAE cells were plated in six-well plates, respectively, at 300 000 and 150 000 cells/ well. After one day, cells were transfected with a luciferase construct controlled by serum response elements (0.5 mg) or STAT-response elements (GRR5, 0.5 mg), 2 in the presence of Fugene HD (for MCF7, Promega) or Lipofectamine 2000 (for PAE, Invitrogen). After 24 h, cells were lysed and luciferase activity was measured recommended by the manufacturer (Promega). b-Galactosidase levels were used to normalize the results as described. 42 Modeling methods Spatial structures of the dimers formed by transmembrane helical fragments of the WT PDGFRA and its V536E mutant were built using PREDDIMER algorithm starting from their sequences (see Figure 5b) as described elsewhere. 26 For calculations of backbone root-mean-square deviations between the predicted models and PDGFRB transmembrane dimer, its nuclear magnetic resonance structure was used (2L6W 27 ). Packing efficiencies of the predicted dimers were estimated according to values of PREDDIMER scoring function (F SCOR ). Normalized values of F C SCOR for a combined set of three top ranked of PDGFRA-WT and PDGFRA-V536E dimer conformations were calculated as: F C SCOR ¼ (F SCOR À /F SCOR S)/ std.F SCOR , where /F SCOR S and std.F SCOR are the mean and standard deviation within the set.
